Phase 1 trial of ruxolitinib, a JAK1 inhibitor for preventing GVHD

Investigating biomarker-guided ruxolitinib for preventing chronic GVHD in post-transplant patients, this Phase 1 trial compares ruxolitinib monotherapy starting about 105 days after allogeneic HCT versus standard-of-care treatment. Targeting patients at high risk for chronic GVHD following transplant for blood and bone marrow malignancies, the study seeks improved long-term outcomes and is sponsored by City of Hope Medical Center.